Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Condition: Cancer
MeSH terms: Lymphoma
Study type: Interventional
Phase: Phase 1

Summary: 
      RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's
      lymphoma by stopping blood flow to the cancer.

      PURPOSE: This phase I trial is studying the side effects of VEGF Trap in treating patients
      with relapsed or refractory advanced solid tumors or non-Hodgkin's lymphoma.
    

Detailed description: 
      OBJECTIVES:

      Primary

        -  Determine the safety and tolerability of intravenous VEGF Trap in patients with relapsed
           or refractory advanced solid tumors or non-Hodgkin's lymphoma.

      Secondary

        -  Determine the steady-state pharmacokinetics of this drug in these patients.

        -  Determine the ability of this drug to bind circulating vascular endothelial growth
           factor in these patients.

        -  Determine whether antibodies to this drug develop in these patients.

        -  Determine, preliminarily, the ability of repeated doses of this drug to alter tumor
           growth and vascular permeability in these patients.

      OUTLINE: This is an open-label, multicenter, extension study.

      Patients receive VEGF Trap* IV over 1 hour on day 1. Courses repeat every 14 days in the
      absence of disease progression or unacceptable toxicity.

      NOTE: *Patients receive the same drug dose that they received in MSKCC-03137 (VGFT-ST-0202)

      Patients are followed monthly for 3 months.

      PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study within 3-6 months.
    

Intervention name(s): ziv-aflibercept
Intervention type(s): Biological
Intervention MeSH terms: Aflibercept
Intervention model: Single Group Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: recurrent grade 1 follicular lymphoma; stage IV grade 1 follicular lymphoma; recurrent grade 2 follicular lymphoma; stage IV grade 2 follicular lymphoma; recurrent grade 3 follicular lymphoma; stage IV grade 3 follicular lymphoma; recurrent adult diffuse small cleaved cell lymphoma; stage IV adult diffuse small cleaved cell lymphoma; recurrent adult diffuse large cell lymphoma; stage IV adult diffuse large cell lymphoma; recurrent adult diffuse mixed cell lymphoma; stage IV adult diffuse mixed cell lymphoma; recurrent adult immunoblastic large cell lymphoma; stage IV adult immunoblastic large cell lymphoma; recurrent adult Burkitt lymphoma; stage IV adult Burkitt lymphoma; recurrent mantle cell lymphoma; stage IV mantle cell lymphoma; recurrent adult lymphoblastic lymphoma; stage IV adult lymphoblastic lymphoma; unspecified adult solid tumor, protocol specific; recurrent adult soft tissue sarcoma; advanced adult primary liver cancer; recurrent adult primary liver cancer; recurrent cervical cancer; stage IVA cervical cancer; stage IVB cervical cancer; fallopian tube cancer; ovarian sarcoma; recurrent ovarian epithelial cancer; stage IV ovarian epithelial cancer; recurrent endometrial carcinoma; stage IV endometrial carcinoma; recurrent uterine sarcoma; stage IV uterine sarcoma; recurrent ovarian germ cell tumor; stage IV ovarian germ cell tumor; ovarian stromal cancer; recurrent vaginal cancer; stage IVA vaginal cancer; stage IVB vaginal cancer; recurrent prostate cancer; stage IV prostate cancer; recurrent penile cancer; stage IV penile cancer; recurrent malignant testicular germ cell tumor; stage III malignant testicular germ cell tumor; recurrent bladder cancer; stage IV bladder cancer; recurrent vulvar cancer; stage IVB vulvar cancer; distal urethral cancer; proximal urethral cancer; recurrent urethral cancer; urethral cancer associated with invasive bladder cancer; primary peritoneal cavity cancer; recurrent marginal zone lymphoma; recurrent small lymphocytic lymphoma; stage IV small lymphocytic lymphoma; stage IV marginal zone lymphoma; extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue; nodal marginal zone B-cell lymphoma; splenic marginal zone lymphoma; stage IV adult soft tissue sarcoma